953422-53-2

Upstream product

• 2987-16-8 3,3-dimethylbutyrylaldehyde 
• 619-44-3 methyl 4-iodobenzoate 
• 630-17-1 2,2-dimethylpropyl bromide 
• 1571-08-0 methyl 4-formylbenzoate 
• 13132-23-5 2,2-dimethylpropylmagnesium chloride 

Downstream Products

• 953422-54-3 4-[1-(4-bromo-3,5-dimethyl-phenoxy)-3,3-dimethyl-butyl]-benzoic acid methyl ester 
• 908247-24-5 4-((E)-3,3-Dimethyl-but-1-enyl)-benzoic acid 

Relevant academic research and scientific papers

GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the

AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME

Abstract of the Disclosure Compounds are disclosed that have a formula represented by Formula I herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals in